Deferred combined androgen blockade therapy using bicalutamide in patients with hormone-refractory prostate cancer during androgen deprivation monotherapy

BJU International

Volumn 97, Issue 6, 2006, Pages 1184-1189

  Fujii, Yasuhisa ^a   Kawakami, Satoru ^a   Masuda, Hitoshi ^a   Kobayashi, Tsuyoshi ^a   Hyochi, Nobuhiko ^a   Kageyama, Yukio ^a   Kihara, Kazunori ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Bicalutamide; Combined androgen blockade; Prostate cancer; Prostate specific antigen

Indexed keywords

ANDROGEN; ANTIANDROGEN; BICALUTAMIDE; GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANDROGEN BLOCKADE THERAPY; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER HORMONE THERAPY; CANCER RELAPSE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; LIVER DYSFUNCTION; MALE; NAUSEA; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; TREATMENT OUTCOME; WITHDRAWAL SYNDROME;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANILIDES; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 33745184443     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2006.06149.x     Document Type: Article

References (29)

1. Denis L, Murphy GP. Overview of phase III trials on combined androgen treatment in patients with metastatic prostate cancer. Cancer 1993 72: 3888 95
2. Newling DW, Denis L, Vermeylen K. Orchiectomy versus goserelin and flutamide in the treatment of newly diagnosed metastatic prostate cancer. Analysis of the criteria of evaluation used in the European Organization for Research and Treatment of Cancer - Genitourinary Group Study 30853. Cancer 1993 72: 3793 8
3. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer. An overview of the randomised trials. Lancet 2000 355: 1491 8
4. Schmitt B, Bennett C, Seidenfeld J, Samson D, Wilt T. Maximal androgen blockade for advanced prostate cancer. Cochrane Database Syst Rev 2000 CD001526
5. Schmitt B, Wilt TJ, Schellhammer PF et al. Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer: a systematic review. Urology 2001 57: 727 32
6. Samson DJ, Seidenfeld J, Schmitt B et al. Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer 2002 95: 361 76
7. Laufer M, Denmeade SR, Sinibaldi VJ, Carducci MA, Eisenberger MA. Complete androgen blockade for prostate cancer: what went wrong? J Urol 2000 164: 3 9
8. Loblaw DA, Mendelson DS, Talcott JA et al. American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. J Clin Oncol 2004 22: 2927 41
9. Scher HI, Steineck G, Kelly WK. Hormone-refractory (D3) prostate cancer: refining the concept. Urology 1995 46: 142 8
10. Ryan CJ, Small EJ. Role of secondary hormonal therapy in the management of recurrent prostate cancer. Urology 2003 62 ( Suppl. 1 87 94
11. Fossa SD, Slee PH, Brausi M et al. Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a phase III study of the European organization for research and treatment of cancer genitourinary group. J Clin Oncol 2001 19: 62 71
12. Fowler JE Pandey P, Seaver LE, Feliz TP. Prostate specific antigen after gonadal androgen withdrawal and deferred flutamide treatment. J Urol 1995 154: 448 53
13. Fujikawa K, Matsui Y, Fukuzawa S, Takeuchi H. Prostate-specific antigen levels and clinical response to flutamide as the second hormone therapy for hormone-refractory prostate carcinoma. Eur Urol 2000 37: 218 22
14. Joyce R, Fenton MA, Rode P et al. High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy. J Urol 1998 159: 149 53
15. Kojima S, Suzuki H, Akakura K, Shimbo M, Ichikawa T, Ito H. Alternative antiandrogens to treat prostate cancer relapse after initial hormone therapy. J Urol 2004 171: 679 83
16. Shulman MJ, Karam JA, Benaim EA. Prostate-specific antigen doubling time predicts response to deferred antiandrogen therapy in men with androgen-independent prostate cancer. Urology 2004 63: 732 6
17. Bubley GJ, Carducci M, Dahut W et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999 17: 3461 7
18. Freedland SJ, Humphreys EB, Mangold LA et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005 294: 433 9
19. Scher HI, Liebertz C, Kelly WK et al. Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. J Clin Oncol 1997 15: 2928 38
20. Halabi S, Small EJ, Kantoff PW et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 2003 21: 1232 7
21. Chen CD, Welsbie DS, Tran C et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004 10: 33 9
22. Koivisto P, Kononen J, Palmberg C et al. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 1997 57: 314 9
23. Palmberg C, Koivisto P, Kakkola L, Tammela TL, Kallioniemi OP, Visakorpi T. Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer. J Urol 2000 164: 1992 5
24. Debes JD, Tindall DJ. Mechanisms of androgen-refractory prostate cancer. N Engl J Med 2004 351: 1488 90
25. Haapala K, Hyytinen ER, Roiha M et al. Androgen receptor alterations in prostate cancer relapsed during a combined androgen blockade by orchiectomy and bicalutamide. Lab Invest 2001 81: 1647 51
26. Culig Z, Hobisch A, Cronauer MV et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 1994 54: 5474 8
27. Klotz L, Schellhammer P, Carroll K. A re-assessment of the role of combined androgen blockade for advanced prostate cancer. BJU Int 2004 93: 1177 82
28. Schellhammer PF, Sharifi R, Block NL et al. Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group. Urology 1997 50: 330 6
29. Akaza H, Yamaguchi A, Matsuda T et al. Superior anti-tumor efficacy of bicalutamide 80 mg in combination with a luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist monotherapy as first-line treatment for advanced prostate cancer: interim results of a randomized study in Japanese patients. Jpn J Clin Oncol 2004 34: 20 8